{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:21:57Z","timestamp":1785352917743,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B. Recent evidence has shown that the synergistic use of flucytosine improves efficacy and reduces toxicity, however affordability and availability has hampered access to flucytosine in many countries. This study investigated the evidence and cost implications of introducing flucytosine as induction therapy for cryptococcal meningitis in HIV-infected adults in South Africa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A decision analytic cost-effectiveness and cost impact model was developed based on survival estimates from the ACTA trial and local costs for flucytosine as induction therapy in HIV-infected adults with cryptococcal meningitis in a public sector setting in South Africa. The model considered five treatment arms: (a) standard of care; 2-week course amphotericin B\/fluconazole (2wk AmBd\/Flu), (b) 2-week course amphotericin B\/flucytosine (2wk AmBd\/5FC), (c) short course; 1-week course amphotericin B\/flucytosine (1wk AmBd\/5FC) (d) oral course; 2-week oral fluconazole\/flucytosine (oral) and e) 1-week course amphotericin B\/fluconazole (1wk AmBd\/Flu). A sensitivity analysis was conducted on key variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The highest total treatment costs are in the 2-week AmBd\/5FC arm followed by the 2-week oral regimen, the 1-week AmBd\/5FC, then standard of care with the lowest cost in the 1-week AmBd\/Flu arm. Compared to the lowest cost option the 1-week flucytosine course is most cost-effective at USD119\/QALY. The cost impact analysis shows that the 1-week flucytosine course has an incremental cost of just over USD293 per patient per year compared to what is currently spent on standard of care. Sensitivity analyses suggest that the model is most sensitive to life expectancy and hospital costs, particularly infusion costs and length of stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The addition of flucytosine as induction therapy for the treatment of cryptococcal meningitis in patients infected with HIV is cost-effective when it is used as a 1-week AmBd\/5FC regimen. Savings could be achieved with early discharge of patients as well as a reduction in the price of flucytosine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-021-06268-9","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T14:02:47Z","timestamp":1617717767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-3826","authenticated-orcid":false,"given":"Jacqui","family":"Miot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simbarashe","family":"Takuva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"issue":"8","key":"6268_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873\u201381. DOI. https:\/\/doi.org\/10.1016\/S1473-3099(17)30243-8.","journal-title":"Lancet Infect Dis"},{"key":"6268_CR2","unstructured":"GERMS-SA Annual Report 2017. Accessed 02 February 2019. Available from: http:\/\/www.nicd.ac.za\/index.php\/publications\/germs-annual-reports\/."},{"issue":"2","key":"6268_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4102\/sajhivmed.v14i2.82","volume":"14","author":"N Govender","year":"2013","unstructured":"Southern African HIV Clinicians Society, Govender N, Meintjes G, Bicanic T, Dawood H, Harrison T, Jarvis KA, et al. Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons. S Afr J HIV Med. 2013;14(2):76\u201386, Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. https:\/\/doi.org\/10.4102\/sajhivmed.v14i2.82.","journal-title":"S Afr J HIV Med"},{"issue":"4","key":"6268_CR4","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1473-3099(18)30493-6","volume":"19","author":"A Loyse","year":"2019","unstructured":"Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro, et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect Dis. 2019;19(4):e143\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(18)30493-6.","journal-title":"Lancet Infect Dis"},{"key":"6268_CR5","unstructured":"WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2018. http:\/\/www.who.int\/hiv\/pub\/guidelines\/cryptococcal-disease\/en\/ (accessed May 2019)."},{"issue":"12","key":"6268_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/jac\/dkw325","volume":"71","author":"M Kneale","year":"2016","unstructured":"Kneale M, Bartholomew J, Davies E, Denning D. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother. 2016;71(12):3599\u2013606. https:\/\/doi.org\/10.1093\/jac\/dkw325.","journal-title":"J Antimicrob Chemother"},{"key":"6268_CR7","unstructured":"Medicines and Related Substances Act (Act 101 of 1965) as amended.\u00a0South African National Department of Health."},{"issue":"1","key":"6268_CR8","doi-asserted-by":"publisher","first-page":"a1030","DOI":"10.4102\/sajhivmed.v20i1.1030","volume":"20","author":"N Govender","year":"2019","unstructured":"Govender N, Meintjies G, Mangena P, Nel J, Potgieter S, Reddy D, et al. South African HIV Clinicians Society guidelines for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. S Afr J HIV Med. 2019;20(1):a1030. https:\/\/doi.org\/10.4102\/sajhivmed.v20i1.1030.","journal-title":"S Afr J HIV Med"},{"issue":"11","key":"6268_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","volume":"378","author":"S Molloy","year":"2018","unstructured":"Molloy S, Kanyama C, Heyderman R, Loyse A, Kouanfack C, Chanda D, et al. ACTA Trial Study Team. Antifungal combinations for treatment of Cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1710922.","journal-title":"N Engl J Med"},{"key":"6268_CR10","doi-asserted-by":"publisher","first-page":"CD005647","DOI":"10.1002\/14651858.CD005647.pub3","volume":"7","author":"MW Tenforde","year":"2018","unstructured":"Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I, Ford N. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:CD005647. https:\/\/doi.org\/10.1002\/14651858.CD005647.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"6268_CR11","unstructured":"South African National Essential Medicine List Adult Hospital Level Medication Review Process Component: HIV and AIDS. NDoH_EDP_Flucytosine_Adults Review_15Nov2018_v2.0. South African National Department of Health."},{"key":"6268_CR12","doi-asserted-by":"publisher","unstructured":"Kanyama C, Molloy SF, Chan AK, Lupiya D, Chawinga C, Adams J, et al. One year mortality outcomes from the ACTA trial of cryptococcal meningitis treatment in Malawi. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz454.","DOI":"10.1093\/cid\/ciz454"},{"issue":"16","key":"6268_CR13","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1097\/QAD.0000000000001197","volume":"30","author":"LF Johnson","year":"2016","unstructured":"Johnson LF, Keiser O, Fox MP, Tanser F, Cornell M, Hoffmann CJ, Prozesky H, Boulle A, Davies MA, International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. International epidemiologic databases to evaluate AIDS Southern Africa (IeDEA-SA) collaboration. Life expectancy trends in adults on antiretroviral treatment in South Africa. AIDS. 2016;30(16):2545\u201350. https:\/\/doi.org\/10.1097\/QAD.0000000000001197.","journal-title":"AIDS."},{"key":"6268_CR14","unstructured":"South African National Department of Health. Publication of the guidelines for pharmacoeconomic submissions. 2013. Government Notice No. R.68, Government Gazette No. 36118. South Africa; 2013."},{"issue":"10159","key":"6268_CR15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/S0140-6736(18)31891-9","volume":"392","author":"GBD 2017 Mortality Collaborators","year":"2018","unstructured":"GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1684\u2013735. https:\/\/doi.org\/10.1016\/S0140-6736(18)31891-9 Global, regional, and national age-sex specific mortality tables for HIV\/AIDS (1980\u20132017) of the Global Burden of Disease study (http:\/\/ghdx.healthdata.org\/gbd-results-tool).","journal-title":"Lancet"},{"issue":"12","key":"6268_CR16","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/cid\/ciw151","volume":"62","author":"M Merry","year":"2016","unstructured":"Merry M, Boulware DR. Cryptococcal meningitis treatment strategies affected by the explosive cost of flucytosine in the United States: a cost-effectiveness analysis. Clin Infect Dis. 2016;62(12):1564\u20138. https:\/\/doi.org\/10.1093\/cid\/ciw151.","journal-title":"Clin Infect Dis"},{"key":"6268_CR17","volume-title":"Master Procurement Catalogue","author":"South African National Department of Health","year":"2018","unstructured":"South African National Department of Health. Master Procurement Catalogue, 2018. http:\/\/www.health.gov.za\/index.php\/component\/phocadownload\/category\/196"},{"issue":"2","key":"6268_CR18","doi-asserted-by":"publisher","first-page":"e0210497","DOI":"10.1371\/journal.pone.021049","volume":"14","author":"G Meyer-Rath","year":"2019","unstructured":"Meyer-Rath G, van Rensburg C, Chiu C, Leuner R, Jamieson L, Cohen S. The per patient costs of HIV services in South Africa: systematic review and application in the south African HIV investment case. PLoS One. 2019;14(2):e0210497. https:\/\/doi.org\/10.1371\/journal.pone.021049.","journal-title":"PLoS One"},{"key":"6268_CR19","volume-title":"Approved UFS 2018 Fee Schedule for full paying patients, Annexure 1A","author":"South African National Department of Health, Uniform Patient Fee Schedule (UPFS)","year":"2018","unstructured":"South African National Department of Health, Uniform Patient Fee Schedule (UPFS) 2018. Approved UFS 2018 Fee Schedule for full paying patients, Annexure 1A."},{"key":"6268_CR20","unstructured":"National Health Laboratory Services. NHLS state Price list 2017. South African National Department of Health."},{"key":"6268_CR21","unstructured":"National Blood Service (SANBS) State Patients Pricelist (1 April 2018 to 31 March 2019).\u00a0South African National Department of Health."},{"key":"6268_CR22","volume-title":"Historical exchange rates (daily) 01 January 2018 to 31","author":"South African Reserve Bank","year":"2018","unstructured":"South African Reserve Bank. Historical exchange rates (daily) 01 January 2018 to 31 2018. https:\/\/www.resbank.co.za\/Research\/Rates\/Pages\/SelectedHistoricalExchangeAndInterestRates.aspx"},{"issue":"4","key":"6268_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1093\/cid\/ciy971","volume":"69","author":"T Chen","year":"2019","unstructured":"Chen T, Mwenge L, Lakhi S, Chanda D, Mwaba P, Molloy SF, Gheorghe A, Griffiths UK, Heyderman RS, Kanyama C, Kouanfack C, Mfinanga S, Chan AK, Temfack E, Kivuyo S, Hosseinipour MC, Lortholary O, Loyse A, Jaffar S, Harrison TS, Niessen LW, ACTA Trial Team. ACTA trial team. Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. Clin Infect Dis. 2019;69(4):588\u201395. https:\/\/doi.org\/10.1093\/cid\/ciy971.","journal-title":"Clin Infect Dis"},{"key":"6268_CR24","volume-title":"Thembisa Model version 4.1: A model for evaluating the impact of HIV\/AIDS in South Africa","author":"L Johnson","year":"2018","unstructured":"Johnson L and Dorrington R. Thembisa Model version 4.1: A model for evaluating the impact of HIV\/AIDS in South Africa 2018. www.thembisa.org."},{"issue":"2","key":"6268_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/QAI.0b013e3181a56f2e","volume":"51","author":"T Bicanic","year":"2009","unstructured":"Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, Hayes M, Jaffar S, Harrison T. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009;51(2):130\u20134. https:\/\/doi.org\/10.1097\/QAI.0b013e3181a56f2e.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"6268_CR26","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1473-3099(18)30493-6","volume":"19","author":"A Loyse","year":"2019","unstructured":"Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, Koulla-Shiro S, Mghamba J, Ramadhani A, Nyirenda R, Aliyu SH, Wilson D, le T, Oladele R, Lesikari S, Muzoora C, Kalata N, Temfack E, Mapoure Y, Sini V, Chanda D, Shimwela M, Lakhi S, Ngoma J, Gondwe-Chunda L, Perfect C, Shroufi A, Andrieux-Meyer I, Chan A, Schutz C, Hosseinipour M, van der Horst C, Klausner JD, Boulware DR, Heyderman R, Lalloo D, Day J, Jarvis JN, Rodrigues M, Jaffar S, Denning D, Migone C, Doherty M, Lortholary O, Dromer F, Stack M, Molloy SF, Bicanic T, van Oosterhout J, Mwaba P, Kanyama C, Kouanfack C, Mfinanga S, Govender N, Harrison TS. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infect Dis. 2019;19(4):e143\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(18)30493-6 Epub 2018 Oct 18.","journal-title":"Lancet Infect Dis"},{"key":"6268_CR27","unstructured":"Boretti N, Meiring S, Quan V, Black JM, Govender N. Amphotericin B and flucytosine combination treatment among patients with HIV-associated cryptococcal meningitis at a tertiary-level hospital in the eastern cape. ePoster 10656, Federation of Infectious Diseases Societies of Southern Africa conference, Johannesburg, South Africa. 2019."},{"issue":"12","key":"6268_CR28","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.1128\/AAC.01698-15","volume":"59","author":"T Bicanic","year":"2015","unstructured":"Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, Jackson A, Phulusa J, Hosseinipour MC, van der Horst C, Limmathurotsakul D, White NJ, Wilson D, Wood R, Meintjes G, Harrison TS, Jarvis JN. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother. 2015;59(12):7224\u201331. https:\/\/doi.org\/10.1128\/AAC.01698-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"6268_CR29","doi-asserted-by":"publisher","first-page":"e0004865","DOI":"10.1371\/journal.pntd.0004865","volume":"10","author":"S Meiring","year":"2016","unstructured":"Meiring S, Fortuin-de Smidt M, Kularatne R, Dawood H, Govender N. GERMS-SA. Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa. PLoS Negl Trop Dis. 2016;10(7):e0004865. https:\/\/doi.org\/10.1371\/journal.pntd.0004865.","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"6268_CR30","doi-asserted-by":"publisher","first-page":"ofy267","DOI":"10.1093\/ofid\/ofy267","volume":"5","author":"R Patel","year":"2018","unstructured":"Patel R, Leeme T, Azzo C, Tlhako N, Tsholo K, Tawanana E, et al. High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B-Based Therapy Under Routine Care Conditions in Africa. Open Forum Infect Dis. 2018;5(11):ofy267. https:\/\/doi.org\/10.1093\/ofid\/ofy267 eCollection 2018 Nov.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"6268_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.7196\/SAMJ.3515","volume":"100","author":"JN Jarvis","year":"2010","unstructured":"Jarvis JN, Meintjes G, Williams Z, Rebe K, Harrison TS. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J. 2010;100(6):378\u201382. https:\/\/doi.org\/10.7196\/SAMJ.3515.","journal-title":"S Afr Med J"},{"issue":"12","key":"6268_CR32","doi-asserted-by":"publisher","first-page":"896","DOI":"10.7196\/SAMJ.9070","volume":"104","author":"N Govender","year":"2014","unstructured":"Govender N, Dlamini S. Management of HIV-associated cryptococcal disease in South Africa. S Afr Med J. 2014;104(12):896. https:\/\/doi.org\/10.7196\/SAMJ.9070.","journal-title":"S Afr Med J"},{"key":"6268_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost \u2013 effectiveness of interventions : alternative approaches. Bull World Health Organ. 2015;93:118\u201324. https:\/\/doi.org\/10.2471\/BLT.14.138206.","journal-title":"Bull World Health Organ"},{"issue":"8","key":"6268_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost- effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929\u201335. ISSN 1524-4733. https:\/\/doi.org\/10.1016\/j.jval.2016.02.017.","journal-title":"Value Health"},{"key":"6268_CR35","volume-title":"South African HIV and TB Investment Case - Summary Report Phase 1. Pretoria","author":"Department of Health, South Africa and South African National AIDS Council","year":"2016","unstructured":"Department of Health, South Africa and South African National AIDS Council: South African HIV and TB Investment Case - Summary Report Phase 1. Pretoria, 2016."},{"issue":"10","key":"6268_CR36","doi-asserted-by":"publisher","first-page":"e0186496","DOI":"10.1371\/journal.pone.0186496","volume":"12","author":"G Meyer-Rath","year":"2017","unstructured":"Meyer-Rath G, van Rensburg C, Larson B, Jamieson L, Rosen S. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017;12(10):e0186496. Published online 2017 Oct 26. https:\/\/doi.org\/10.1371\/journal.pone.0186496.","journal-title":"PLoS One"},{"issue":"9","key":"6268_CR37","doi-asserted-by":"publisher","first-page":"e1001316","DOI":"10.1371\/journal.pmed.1001316","volume":"9","author":"R Rajasingham","year":"2012","unstructured":"Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med. 2012;9(9):e1001316. https:\/\/doi.org\/10.1371\/journal.pmed.1001316.","journal-title":"PLoS Med"},{"key":"6268_CR38","doi-asserted-by":"publisher","unstructured":"Shiri T, Loyse A, Mwenge L, Chen T, Lakhi S, Chanda D, et al. Addition of flucytosine to fluconazole for the treatment of cryptococcal meningitis in Africa: a multi-country cost-effectiveness analysis. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz163 [Epub ahead of print].","DOI":"10.1093\/cid\/ciz163"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06268-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-021-06268-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06268-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T14:08:50Z","timestamp":1617718130000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-06268-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6268"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-06268-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22856\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22856\/v2","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"26 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Research ethics was not required as the study did not involve human subjects or materials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HD has participated as a member of the DSBM in the ACTG (Crytptococcal meningitis) and as an investigator in the ACTG- A 5225 trial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}